Edition:
United States

Bioverativ Inc (BIVV.OQ)

BIVV.OQ on NASDAQ Stock Exchange Global Select Market

103.61USD
16 Feb 2018
Change (% chg)

$0.07 (+0.07%)
Prev Close
$103.54
Open
$103.48
Day's High
$103.75
Day's Low
$103.40
Volume
258,043
Avg. Vol
551,056
52-wk High
$104.30
52-wk Low
$43.55

Select another date:

Tue, Feb 13 2018

BRIEF-Bioverativ Q4 Revenue Rose 28.3 Percent To $328.7 Million

* BIOVERATIV REPORTS FOURTH QUARTER AND FULL YEAR 2017 PERFORMANCE

BRIEF-Sanofi Commences Tender Offer For Acquisition Of Bioverativ

* SANOFI COMMENCES TENDER OFFER FOR ACQUISITION OF BIOVERATIV INC.

Healthcare group Sanofi to buy Ablynx for 3.9 billion euros

PARIS, Jan 29 Sanofi has agreed to buy Belgian biotech company Ablynx for 3.9 billion euros ($4.8 billion), the companies said on Monday, marking the French drug maker's second major takeover deal this month following its acquisition of Bioverativ.

U.S. SEC files suit over possible insider trading on Bioverativ

The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal.

U.S. SEC files suit over possible insider trading on Bioverativ

Jan 26 The U.S. Securities and Exchange Commission filed an insider trading lawsuit on Friday against "unknown traders" who it said engaged in "highly suspicious trading" just ahead of the announcement that hemophilia specialist Bioverativ Inc had agreed to be acquired by France's Sanofi in an $11.6 billion deal.

Sanofi digs deep to buy U.S. hemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. hemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years and a major play to strengthen its presence in treatments for rare diseases. | Video

UPDATE 5-Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 bln

* Shares in Sanofi down 4 percent (Updates shares, adds links to Breakingviews and other stories)

BRIEF-Sanofi CFO sees commercial, cost and tax synergies following Bioverativ deal

Jan 22 Sanofi Chief financial officer Jerome Contamine says :

BRIEF-Bioverativ Says Regarding Termination Of Merger Deal With Sanofi Under Certain Circumstances Co Will Be Required To Pay Fee Of $326 Mln

* BIOVERATIV SAYS REGARDING TERMINATION OF MERGER DEAL WITH SANOFI UNDER CERTAIN CIRCUMSTANCES CO WILL BE REQUIRED TO PAY FEE OF $326 MILLION - SEC FILING Source text: (http://bit.ly/2DC3sg7) Further company coverage:

Sanofi digs deep to buy U.S. haemophilia group Bioverativ for $11.6 billion

PARIS French healthcare group Sanofi has agreed to buy U.S. haemophilia specialist Bioverativ for $11.6 billion, its biggest deal for seven years, which it said would strengthen its presence in treatments for rare diseases. | Video

Select another date: